Novartis announces expiration of Tourmaline Bio tender offer
Basel, October 28 2025 – Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger…
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR…
Trump announces new tariffs on pharmaceuticals from October – The Irish Times
The Government has said a deal capping future US tariffs on imports of pharmaceuticals from Europe still stands,…
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for…
New Novartis ESC data highlights strength of cardiovascular portfolio
PRESS RELEASE Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…